Spyre Therapeutics (SYRE) Assets (2015 - 2026)

Spyre Therapeutics has reported Assets for 12 years, with the latest figure at $764.0 million in Q1 2026.

• For the quarter ending Q1 2026, Assets rose 34.08% year-over-year to $764.0 million; the trailing twelve-month figure through Mar 2026 stood at $764.0 million (up 34.08% YoY), and the FY2025 full-year result was $777.8 million, up 27.82% from the prior year.
• Assets for Q1 2026 stood at $764.0 million, down from $777.8 million in the prior quarter.
• The five-year high for Assets was $777.8 million in Q4 2025, with the low at $52.5 million in Q1 2023.
• Historically, Assets has averaged $370.9 million across 5 years, with a median of $421.1 million in 2024.
• Annual changes were most pronounced in 2022 — Assets plunged 49.17% — and 2024, when it surged 829.6%.
• Spyre Therapeutics' Assets stood at $71.1 million in 2022, then surged by 380.52% to $341.9 million in 2023, then surged by 77.99% to $608.5 million in 2024, then advanced by 27.82% to $777.8 million in 2025, then retreated by 1.78% to $764.0 million in 2026.
• The last three Assets figures came in at $764.0 million (Q1 2026), $777.8 million (Q4 2025), and $504.6 million (Q3 2025), per Business Quant data.